The present study supports work by Burkitt and Ljungman [30], which showed that the HDAC inhibitor phenylbutyrate sensitized cisplatin-resistant head and neck cancer cell lines to cisplatin mediated by the abrogation of the Fanconi anemia/BRCA pathway. The gene discussed is HDAC9; the disease is head and neck cancer.